@article{b4f1cd0ac2d545629d27be30ce40c8ba,
title = "Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a",
abstract = "Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with ",
keywords = "HBV genotype, HBV therapy, Immunomodulator, Nucleos(t)ide analogues, Peginterferon, Quantitative HBsAg",
author = "Vincent Rijckborst and Hansen, {Bettina E.} and Peter Ferenci and Brunetto, {Maurizia R.} and Fehmi Tabak and Yilmaz Cakaloglu and Lanza, {A. Galeota} and Vincenzo Messina and Claudio Iannacone and Benedetta Massetto and Loredana Regep and Massimo Colombo and Janssen, {Harry L A} and Pietro Lampertico",
year = "2012",
month = may,
doi = "10.1016/j.jhep.2011.12.007",
language = "English",
volume = "56",
pages = "1006--1011",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "5",
}